UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Understanding LAG-3 Signaling

International journal of molecular sciences, 2021-05, Vol.22 (10), p.5282

2021

Volltextzugriff (PDF)

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

Cell reports (Cambridge), 2017-08, Vol.20 (8), p.1818-1829

2017

Volltextzugriff (PDF)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

EMBO molecular medicine, 2019-07, Vol.11 (7), p.e10293-n/a

2019

Volltextzugriff (PDF)

The intracellular signalosome of PD-L1 in cancer cells

Signal transduction and targeted therapy, 2018-09, Vol.3 (1), p.26-9, Article 26

2018

Volltextzugriff (PDF)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy

Frontiers in immunology, 2020-11, Vol.11, p.586907-586907

2020

Volltextzugriff (PDF)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

Frontiers in pharmacology, 2020-04, Vol.11, p.441-441

2020

Volltextzugriff (PDF)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

EMBO molecular medicine, 2020-09, Vol.12 (9), p.e12706-n/a

2020

Volltextzugriff (PDF)

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics

Cancers, 2020-02, Vol.12 (2), p.344

2020

Volltextzugriff (PDF)

The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

British journal of cancer, 2022-05, Vol.126 (8), p.1168-1177

2022

Volltextzugriff (PDF)

Hyperprogressive Disease: Main Features and Key Controversies

International journal of molecular sciences, 2021-04, Vol.22 (7), p.3736

2021

Volltextzugriff (PDF)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy

International journal of molecular sciences, 2020-08, Vol.21 (16), p.5918

2020

Volltextzugriff (PDF)

Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives

Archivum Immunologiae et Therapiae Experimentalis, 2018-04, Vol.66 (2), p.113-123

2018

Volltextzugriff (PDF)

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer

International journal of molecular sciences, 2019-04, Vol.20 (7), p.1631

2019

Volltextzugriff (PDF)

Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition

Cancers, 2020-08, Vol.12 (8), p.2181

2020

Volltextzugriff (PDF)

TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy

Frontiers in immunology, 2022-04, Vol.13, p.811867-811867

2022

Volltextzugriff (PDF)

A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating Subsets

Journal of personalized medicine, 2021-06, Vol.11 (6), p.542

2021

Volltextzugriff (PDF)

PD1 signal transduction pathways in T cells

Oncotarget, 2017-08, Vol.8 (31), p.51936-51945

2017

Volltextzugriff (PDF)

Immunotherapy in malignant melanoma: recent approaches and new perspectives

Melanoma management, 2017-03, Vol.4 (1), p.39-48

2017

Volltextzugriff (PDF)

Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy

EMBO molecular medicine, 2019-07, Vol.11 (7), p.e10293

2019

Volltextzugriff (PDF)

Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives

Archivum Immunologiae et Therapiae Experimentalis, 2018-04, Vol.66 (2), p.113-123

2018

Volltextzugriff (PDF)

PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

EMBO molecular medicine, 2024-07, Vol.16 (8), p.1791-1816

2024

Volltextzugriff (PDF)

The multi-specific V H -based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

British journal of cancer, 2022-05, Vol.126 (8), p.1168

2022

Volltextzugriff (PDF)

Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy

Annals of translational medicine, 2017-10, Vol.5 (19), p.385-385

2017

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(31)
Tagungsberichte
(1)

Sprache

Englisch
(32)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Understanding LAG-3 Signaling

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

The intracellular signalosome of PD-L1 in cancer cells

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics

The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

Hyperprogressive Disease: Main Features and Key Controversies

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy

Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer

Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition

TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy

A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating Subsets

PD1 signal transduction pathways in T cells

Immunotherapy in malignant melanoma: recent approaches and new perspectives

Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy

Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives

Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer

PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

The multi-specific V H -based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy

Suchergebnisse filtern